Showing 3461-3470 of 6035 results for "".
- GenSight Biologics Withdraws its EMA Application for Lumevoqhttps://modernod.com/news/gensight-biologics-withdraws-its-ema-application-for-lumevoq/2481559/GenSight Biologics announced that it has decided to withdraw an application with the European Medicines Agency (EMA) seeking approval of Lumevoq (lenadogene nolparvovec) in patients with Leber hereditary optic neuropathy (LHON). The moves comes after the Committee for Advanced Therapies (CAT
- Ocugen to Present on Modifier Gene Therapy Platform at ARVO 2023https://modernod.com/news/ocugen-to-present-on-modifier-gene-therapy-platform-at-arvo-2023/2481547/Ocugen announced that the company will present on its modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa and Leber congenital amaurosis; OCU410 for the treatment dry age-related macular degeneration (dry AMD); OCU410ST for the treatment of St
- Aviceda Announces FDA Clearance of the IND Application Enabling Phase 2 Trials for GA Drug Candidatehttps://modernod.com/news/aviceda-announces-fda-clearance-of-the-ind-application-enabling-phase-2-trials-for-geographic-atrophy-drug-candidate/2481529/Aviceda Therapeutics announced that the FDA has cleared the IND for AVD-104, enabling the company to proceed with initiating phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Pha
- Lumata Health and Prevent Blindness Announce Partnership Aimed at Delivering More Resources to Americans with Vision Losshttps://modernod.com/news/lumata-health-and-prevent-blindness-announce-partnership-aimed-at-delivering-more-resources-to-americans-with-vision-loss/2481522/Lumata Health announced a partnership with Prevent Blindness which will focus on various initiatives to address barriers to care for patients, with a strong focus on mental health resources to start. “Our care coordinators are in frequent contact with pati
- CDC: Cases of Vision Loss and Death Due to Drug-Resistant Bacteria Linked to Artificial Tears Continues to Risehttps://modernod.com/news/cdc-cases-of-vision-loss-and-death-due-to-drug-resistant-bacteria-linked-to-artificial-tears-continues-to-rise/2481488/Federal officials say three people have died as part of a growing number of cases of infections from a rare, extensively drug-resistant strain of Pseudomonas aeruginosa found in some artificial tears. There have also been 8 reports of vision loss and 4 reports of enucleatio
- OcuSciences Announces Publication Showing Potential to Detect Retinal Diseases with High Sensitivityhttps://modernod.com/news/ocusciences-announces-publication-showing-potential-to-detect-retinal-diseases-with-high-sensitivity/2481484/OcuSciences announced a publication in
- BioCareSD and AllyRetina GPO Partner to Help Retina Providers Improve Patient Care and Increase Efficiencyhttps://modernod.com/news/biocaresd-and-allyretina-gpo-partnership-to-help-retina-providers-improve-patient-care-and-increase-efficiency/2481473/BioCareSD announced its partnership with AllyRetina. Debuting at the American Society of Retina Specialists (ASRS) 24th Annual Business of Retina conference this week, AllyRetina will serve its GPO members through its physician leadership, a seasoned management team, and innovative tools and
- EyeBio Announces First Asset in Pipeline of Retinal Disease Treatments and Appoints New Members to Executive Teamhttps://modernod.com/news/eyebio-announces-first-asset-in-pipeline-of-retinal-disease-treatments-and-appoints-new-members-to-executive-team/2481448/Eyebiotech Limited announced several appointments to its executive team and announced details on Restoret, the first asset in a pipeline of multi-specific agonist antibodies. EyeBio announced the following appointments to the senior leadership team: Anthony P. Adami
- Glaukos Submits NDA to FDA for iDose TRhttps://modernod.com/news/glaukos-submits-nda-to-fda-for-idose-tr/2481434/Glaukos announced the submission of a new drug application (NDA) to the FDA for iDose TR, a micro-invasive intraocular implant designed to continuously deliver therapeutic levels of a proprietary formulation of travoprost from within the eye for extended periods of time.&
- Envision University Sets Agenda for In-Person Spring 2023 Conferencehttps://modernod.com/news/envision-university-sets-agenda-for-in-person-spring-2023-conference/2481426/The agenda has been set for the Envision Conference West, which will be held in collaboration with UT Health Department of Occupational Therapy, March 30-April 1, 2023, at the Academic Learning and Teaching Center of UT Health in San Antonio, Texas. The Envision Conference is the only multid